Description
Capitalizing on the latest breakthroughs in Targeted Protein Degradation (TPD), CD ComputaBio provides an innovative KineTACs Design and Development Service. KineTACs represent a novel therapeutic modality targeting kinase-mediated signaling pathways. Our computational platform assists in the rational design of these bifunctional molecules by simulating ternary complex formation, evaluating optimal linker lengths, and analyzing the spatial cooperation between target kinases and specific degradation machinery, driving rapid advancement in oncology and precision medicine pipelines.